Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs Semaglutide on Islet Function in T2DM
NCT03951753Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Clamp Disposition Index at Week 28. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03951753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951753.